Bryan M. Burt, MD, FACS

One of Dr. Burt's primary cancer-relevant research interests is determining biomarkers, and mechanisms of response and resistance to immunotherapy in thoracic malignancies. Another one of his primary interests is investigating the use of a novel mass spectrometry platform to improve the intraoperative diagnosis and assessment of surgical margins in thoracic malignancies.

Lee HS, Jang HJ, Ramineni M, Wang DY, Ramos D, Choi JM, Splawn T, Espinoza M, Almarez M, Hosey L, Jo E, Hilsenbeck S, Amos CI, Ripley RT, Burt BM. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023 Feb 1;29(3):548-559. PMID 36469573. PMCID: PMC9898180

Jang HJ, Lee HS, Yu W, Ramineni M, Truong C, Ramos D, Splawn T, Choi JM, Jung SY, Lee JS, Wang Y, Sederstrom J, Pietropaolo M, Kheradmand F, Amos C, Wheeler TM, Ripley RT, Burt BM. Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor- Immune Microenvironment. Cancer Res. 2022; 18;82(14):2593-2609. PMID: 35709756. *Cover Article

Nash AM, Aghlara-Fotovat S, Castillo B, Hernandez A, Pugazenthi A, Lee HS, Nguyen A, Lu A, Burt BM, Ghanta R, Veiseh O. A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma. Clin Cancer Res. 2022. doi:10.1158/1078-0432.CCR-22-1493. PMID: 35993913

Lee HS, Hamaji M, Palivela N, Jang HJ, Splawn T, Ramos D, Lee AK, Raghuram AC, Ramineni M, Amos CI, Ripley RT, Burt BM. Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma. Ann Thorac Surg. 2021 Nov;112(5):1575 1583. doi: 10.1016/j.athoracsur.2020. PMID: 33248997

Jang HJ, Lee HS, Ramos D, Park IK, Kang CH, Burt BM, Kim YT. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors. J Thorac Cardiovasc Surg. 2020 Apr;159(4):1598-1610.e3. doi: 10.1016/j.jtcvs.2019.10.123. PMID: 31632788 PMCID: PMC6783787